한빛사논문
- 조회819
Hyun-Woo Choi, M.D., Ph.D.1*, Ju-Hyeon Shin, M.D.1*, Seung-Jung Kee, M.D., Ph.D.1‡, Yong-Soo Kwon, M.D., Ph.D.2, Taeo Ma, M.D.1, Hyun-Seung Lee, M.D., Ph.D.1, Sejong Chun, M.D.1, Eun Jeong Won, M.D., Ph.D.1,3, Jong-Hee Shin, M.D., Ph.D.1
1 Department of Laboratory Medicine and 2 Department of Pulmonary and Critical Care Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea; and 3Department of Parasitology, Chonnam National University Medical School, Gwangju, Republic of Korea
*These authors contributed equally to this work and are joint first authors.
‡ Corresponding author: Seung-Jung Kee, M.D., Ph.D.; Department of Laboratory Medicine, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Republic of Korea
Abstract
We thank Dr. Aubry and Dr. Veziris for their letter and great interest in our published study (1). They raised concerns regarding the possibility of delaying the diagnosis of non-tuberculous mycobacteria (NTM) diseases when using Xpert MTB/RIF assay alone. We consider that the clinical benefit of early diagnosis or exclusion of tuberculosis, relying solely on the Xpert MTB/RIF results, is more important than the disadvantage that could result from delayed diagnosis of NTM disease. Moreover, this weakness can be minimized by considering the current diagnostic criteria for NTM lung disease (2). The reasons are as follows.
논문정보
- Correspondence
- 2019년 06월 (BRIC 등록일 2019-06-26)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
